Clinical Topics & News
Conference Coverage
Alemtuzumab-induced autoimmunity: getting closer to answers
Researchers are getting closer to identifying MS patients more susceptible to secondary autoimmunity after alemtuzumab treatment.
Conference Coverage
High dose of novel compound for relapsing-remitting MS shows promise
SAN DIEGO – Evidence of remyelination observed at 24 weeks.
Literature Review
ECTRIMS and EAN Publish Recommendations for Treating MS
The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) have published a...
Conference Coverage
Fingolimod switch from an injectable linked to improved outcomes in relapsing MS
SAN DIEGO – The benefit of the switch was observed regardless of previous treatment status.
Conference Coverage
Extended-interval dosing of natalizumab linked to lower risk of PML
SAN DIEGO – Dangerous viral brain disease is more likely to strike at-risk MS patients who rely on standard-interval dosing.
Conference Coverage
VIDEO: Teriflunomide and dimethyl fumarate are comparable in relapsing-remitting MS
SAN DIEGO – Small study of oral drugs finds they’re similar in terms of efficacy and adverse effects, and both can be used “with equal confidence...
Conference Coverage
‘Real-world evidence’ used to compare agents for relapsing-remitting MS
SAN DIEGO – The comparative effectiveness of delayed-release dimethyl fumarate was analyzed against fingolimod and glatiramer acetate.
Literature Review
MAGNIMS and McDonald Criteria Have Similar Accuracy
The 2016 Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) criteria have accuracy similar to that of the 2010 McDonald criteria in...
Literature Review
Rituximab May Provide Greater Benefits Than Other First-Line MS Therapies
Rituximab is associated with a lower drug discontinuation rate than all other commonly prescribed disease-modifying treatments (DMTs) used as...
Article
MS: Past, Present, and Future
Stuart D. Cook, MD, and Abdul Rahman Alchaki, MDDr. Cook is the Ruth Dunietz Kushner and Michael Jay Serwitz Professor of Neurology/Neurosciences...